Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by TNFSF15 is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. Additionally we are shipping TNFSF15 Proteins (34) and TNFSF15 Kits (9) and many more products for this protein.
Showing 10 out of 180 products:
Human Polyclonal TNFSF15 Primary Antibody for FACS, IF - ABIN655822
Amre, Mack, Morgan, Israel, Deslandres, Seidman, Lambrette, Costea, Krupoves, Fegury, Dong, Xhu, Grimard, Levy: Association between genome-wide association studies reported SNPs and pediatric-onset Crohn's disease in Canadian children. in Human genetics 2010
Show all 5 references for ABIN655822
Human Polyclonal TNFSF15 Primary Antibody for EIA, IF - ABIN955278
Heidemann, Chavez, Landers, Kucharzik, Prehn, Targan: TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets. in Journal of clinical immunology 2010
Show all 5 references for ABIN955278
Human Polyclonal TNFSF15 Primary Antibody for EIA, WB - ABIN500934
Kitson, Raven, Jiang, Goeddel, Giles, Pun, Grinham, Brown, Farrow: A death-domain-containing receptor that mediates apoptosis. in Nature 1996
Human Polyclonal TNFSF15 Primary Antibody for IF (p), IHC (p) - ABIN709556
?lebioda, Bojarska-Junak, Stanis?awowski, Cyman, Wierzbicki, Roli?ski, Celi?ski, Kmie?: TL1A as a potential local inducer of IL17A Expression in colon mucosa of inflammatory bowel disease patients. in Scandinavian journal of immunology 2015
Human Polyclonal TNFSF15 Primary Antibody for EIA, IHC (p) - ABIN500933
Chinnaiyan, ORourke, Yu, Lyons, Garg, Duan, Xing, Gentz, Ni, Dixit: Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. in Science (New York, N.Y.) 1996
(188)Re-NGR (show RTN4R Antibodies)-VEGI has the potential as a theranostic agent.
miRNA-31 can directly bind to the 3-UTR (show UTS2R Antibodies) of TNFSF15, thereafter negatively regulating its expression in Caco2 cells.
Patients with mild traumatic brain injury (TBI) exhibited higher VEGI levels than those with moderate and severe TBI.
Biologics beyond TNF-alpha (show TNF Antibodies) inhibitors and the effect of targeting the homologues TL1A-DR3 (show TNFRSF25 Antibodies) pathway in chronic inflammatory disorders.
Rs3810936 of TNFSF15 were related to the risk of ankylosing spondylitis
Higher TL1A levels were associated with early stage chronic lymphocytic leukemia.
TL1A-induced cell death is directly mediated through DR3 (show TNFRSF25 Antibodies).
Plasma levels of TL1A were significantly higher in newly diagnosed SLE patients compared with controls, and were positively associated with SLE disease activity index.
This study indicates that the HDAC (show HDAC3 Antibodies) inhibitor may be exploited as a therapeutic strategy modulating the soluble VEGI/DR3 (show TNFRSF25 Antibodies) pathway in osteosarcoma patients
Results show that subjects with TNFSF15 -358CC genotype were at higher risks for developing gastric adenocarcinoma in the Helicobacter pylori infected group.
These data demonstrated a direct role for TL1A-DR3 (show TNFRSF25 Antibodies) signaling in tissue fibrosis and that modulation of TL1A-DR3 (show TNFRSF25 Antibodies) signaling could inhibit gut (show GUSB Antibodies) fibrosis.
these data identify TL1A-DR3 (show TNFRSF25 Antibodies) interactions as a novel pathway that promotes Th9 differentiation and pathogenicity. TL1A may be a potential therapeutic target in diseases dependent on IL-9 (show IL9 Antibodies).
TL1A induces NF-kappaB (show NFKB1 Antibodies) activation in EC in renal and cardiac tissue from wild type but not DR3 (show TNFRSF25 Antibodies) knock-out mice.
TL1A deficiency impacts on the gut (show GUSB Antibodies) microbial composition and the mucosal immune system, especially the intraepithelial TCRgammadelta(+) T-cell subset, and that TL1A is involved in the establishment of adipose tissue.
Our data demonstrate a key role for TL1A in promoting ILC2s at mucosal barriers.
TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor (show FLT1 Antibodies) 1.
Both in supernatant and as purified fusion protein, TL1A-Ig binds to TNFRSF25 (show TNFRSF25 Antibodies) transfected--but not untransfected--P815 tumor cells as determined by flow cytometry.
These results establish a novel link between tumor necrosis factor (TNF (show TNF Antibodies))-family cytokine TL1A (TNFSF15) and interleukin 13 (IL-13 (show IL13 Antibodies)) responses that results in small intestinal inflammation.
role of TL1A in mucosal T cells and antigen presenting cells function and showed that up-regulation of TL1A expression can promote mucosal inflammation and gut (show GUSB Antibodies) fibrosis.
findings suggest that the transcription factor NF-kappaB (show NFKB1 Antibodies) plays an important role in the regulation of VEGI expression
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. Two transcript variants encoding different isoforms have been found for this gene.
tumor necrosis factor ligand superfamily member 15
, vascular endothelial growth inhibitor
, tocopherol (alpha) transfer protein-like
, TNF ligand-related molecule 1
, TNF superfamily ligand TL1A
, vascular endothelial cell growth inhibitor
, vascular endothelial growth inhibitor-192A
, bM20K13.3 (tumor necrosis factor (ligand) superfamily, member 15)